share_log

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(0.0%)

SEC announcement ·  Feb 13 01:00
Summary by Futu AI
Janus Henderson Group plc, an investment firm based in Jersey, Channel Islands, has filed an amended Schedule 13G/A with the United States Securities and Exchange Commission on February 12, 2024, indicating that they now own less than 5% of Altimmune, Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reflects a change in ownership status as Janus Henderson's managed portfolios no longer hold a significant stake in Altimmune's common stock. The shares were held by Janus Henderson's subsidiaries, including Janus Henderson Investors U.S. LLC, Janus Henderson Investors UK Limited, and Janus Henderson Investors Australia Institutional Funds Management Limited, which are collectively referred to as the Asset Managers. The Asset Managers are registered investment advisers that provide investment advice to various funds and clients. The filing emphasizes that the shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune.
Janus Henderson Group plc, an investment firm based in Jersey, Channel Islands, has filed an amended Schedule 13G/A with the United States Securities and Exchange Commission on February 12, 2024, indicating that they now own less than 5% of Altimmune, Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reflects a change in ownership status as Janus Henderson's managed portfolios no longer hold a significant stake in Altimmune's common stock. The shares were held by Janus Henderson's subsidiaries, including Janus Henderson Investors U.S. LLC, Janus Henderson Investors UK Limited, and Janus Henderson Investors Australia Institutional Funds Management Limited, which are collectively referred to as the Asset Managers. The Asset Managers are registered investment advisers that provide investment advice to various funds and clients. The filing emphasizes that the shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.